A Phase I Bayesian Adaptive Design to Simultaneously Optimize Dose and Schedule Assignments Both Between and Within Patients

DOI10.1080/01621459.2013.806927OpenAlexW2019966306WikidataQ37291757 ScholiaQ37291757MaRDI QIDQ2861803FDOQ2861803

Authors: Thomas M. Braun, Jin Zhang 

Publication date: 11 November 2013

Published in: Journal of the American Statistical Association (Search for Journal in Brave)

Full work available at URL: http://europepmc.org/articles/pmc3821780

zbMATH Keywords

Bayesian statisticsclinical trialdynamic treatment regimedose-escalation studynonmixture cure model

Mathematics Subject Classification ID

Statistics (62-XX)

Cites Work

• AMCMC: an R interface for adaptive MCMC
• Analysis of multivariate survival data
• Continual Reassessment Method: A Practical Design for Phase 1 Clinical Trials in Cancer
• Sequential Designs for Phase I Clinical Trials with Late‐Onset Toxicities
• A nonidentifiability aspect of the problem of competing risks.
• Optimal Dynamic Treatment Regimes
• Bayesian Model Averaging Continual Reassessment Method in Phase I Clinical Trials
• Determining a Maximum‐Tolerated Schedule of a Cytotoxic Agent

Cited In (6)

• Bayesian dose regimen assessment in early phase oncology incorporating pharmacokinetics and pharmacodynamics
• DICE: A Bayesian model for early dose finding in phase I trials with multiple treatment courses
• Pharmacokinetically guided optimum adaptive dose selection in early phase clinical trials
• Bayesian modeling of a bivariate toxicity outcome for early phase oncology trials evaluating dose regimens
• A Bayesian time-to-event pharmacokinetic model for phase I dose-escalation trials with multiple schedules
• Adaptive clinical trial designs for phase I cancer studies

This page was built for publication: A Phase I Bayesian Adaptive Design to Simultaneously Optimize Dose and Schedule Assignments Both Between and Within Patients

Report a bug (only for logged in users!)Click here to report a bug for this page (MaRDI item Q2861803)